This shows you the differences between two versions of the page.
Next revision | Previous revisionLast revisionBoth sides next revision | ||
home:publications:heil_autoimmunity_2016 [04.30.2016] – created detruth | home:publications:heil_autoimmunity_2016 [05.01.2016] – [Abstract] text of abstract broken into two paragraphs joyful | ||
---|---|---|---|
Line 8: | Line 8: | ||
**Location: | **Location: | ||
**Date: | **Date: | ||
- | **Additional Content: | + | **Additional Content: |
Line 15: | Line 15: | ||
- | Due to the increasingly complex and comorbid nature of chronic inflammatory and auto-immune disorders, treatment of these conditions calls for a new approach, as many patients do not respond to current treatment modalities. Seven years ago, we began exploring a novel immuno-modulating monotherapy to volunteer patients using a retargeted drug, olmesartan medoxomil, which, when dosed more frequently than usual, stimulates the innate immune system by acting as a VDR nuclear receptor agonist. Patients who had previously failed to respond to long term “standard of care,” “feel better” palliative, immune suppressive therapy associated with significant relapse rates were no longer interested in defensively managing their conditions with unscientifically based expectations of recovery. Instead, these patients engaged in long-term novel offensive positioning and effective treatment which involved “feeling worse at first” accompanied by synergistic immune stimulation, | + | Due to the increasingly complex and comorbid nature of chronic inflammatory and auto-immune disorders, treatment of these conditions calls for a new approach, as many patients do not respond to current treatment modalities. Seven years ago, we began exploring a novel immuno-modulating monotherapy to volunteer patients using a retargeted drug, olmesartan medoxomil, which, when dosed more frequently than usual, stimulates the innate immune system by acting as a VDR nuclear receptor agonist. Patients who had previously failed to respond to long term “standard of care,” “feel better” palliative, immune suppressive therapy associated with significant relapse rates were no longer interested in defensively managing their conditions with unscientifically based expectations of recovery. Instead, these patients engaged in long-term novel offensive positioning and effective treatment which involved “feeling worse at first” accompanied by synergistic immune stimulation, |
+ | |||
+ | Sixty-two (62) volunteer patients from a nurse practitioner practice in Arizona were admitted as participants in this observational cohort between 2008 and 2012. Conventional clinical symptoms were monitored using a consistent 10-point self-reporting scale at each encounter. Self-reported symptoms monitored include: insomnia, depression, incontinence, | ||
{{tag> | {{tag> | ||